RecruitingNCT07520292
NTX-2001 for reducing alcohol consumption
About this title
Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder
Read the official source — NCT07520292Medication studyAges 21–60United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 21 years to 60 years.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 20, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- Newleos Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 21 Years to 60 Years
- Official registry ID
- NCT07520292
- Official title
Show the full official title
The Effects of NTX-2001, a Novel TAAR1 Partial Agonist, on Alcohol Consumption in Adults With Alcohol Use Disorder: A Phase 1b, Randomized, Placebo-Controlled, Proof-of-Concept Study
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New Haven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Newleos Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including NTX-2001 and Placebo.
Who can participate?
Listed age limits: 21 years to 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
